Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Granulocyte colony stimulating factor - Xenetic Biosciences/SynBio

Drug Profile

Granulocyte colony stimulating factor - Xenetic Biosciences/SynBio

Alternative Names: Polysialic G-CSF - Xenetic Biosciences; StimuXen; SYN 20111504RU

Latest Information Update: 11 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lipoxen Technologies; Serum Institute of India
  • Developer Serum Institute of India; SynBio; Xenetic Biosciences
  • Class Adjuvants; Glycoproteins; Granulocyte colony-stimulating factors; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Neutropenia

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 16 Jun 2014 Granulocyte colony stimulating factor polysialic licensed to SynBio worldwide prior to April 2014
  • 15 Apr 2014 Preclinical trials in Neutropenia in Russia (Parenteral) prior to April 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top